Psychedelics Investing Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Psychedelics Investing Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Psychedelics Investing Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Psychedelics Investing Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
